Introduction {#s0005}
============

Sulfasalazine (SSZ; salazopyrin, sulfasalazopyridine, salicylazosulfapyridine) is a U.S. Food and Drug Administration--approved disease-modifying antirheumatic drug (DMARD) commonly used in the treatment of rheumatoid arthritis and ulcerative colitis ([@b0280]). Owing to its anti-inflammatory action, SSZ is used off-label in a wide spectrum of dermatological diseases; however, there is dearth of literature on its use in dermatology.

History {#s0010}
=======

SSZ was devised by Dr. Nana Svartz, a Scandinavian rheumatologist and professor of medicine at the Karolinska Institute in Stockholm, in cooperation with Swedish pharmaceutical company Pharmacia in 1941. It was an attempt to treat rheumatoid arthritis (then known as rheumatic polyarthritis), which was believed to be a disease of bacterial origin. It was observed that when given concomitantly, sulfonamides and aspirin did not produce concrete results, which shifted the research focus to combining the two agents chemically to produce an antibiotic that would have an affinity for connective tissue. The result was the drug SSZ, which was first tried in rheumatic polyarthritis with impressive results and later in ulcerative colitis ([@b0100], [@b0315], [@b0350]). The use of SSZ in dermatology can be traced back to 1971 when it was first used in scleroderma ([@b0100]).

Pharmacokinetics {#s0015}
================

Absorption {#s0020}
----------

SSZ is the combination of a sulfonamide (sulfapyridine) and mesalazine (mesalamine, 5-aminosalicylic acid) covalently linked by an azo bond. It is absorbed in the small intestine with an oral bioavailability of approximately 10% to 30%. SSZ that reaches the large bowel undergoes azoreduction by bacterial azoreductases to release sulfapyridine and mesalazine. Sulfapyridine is almost fully (\>90%) absorbed, whereas mesalazine undergoes only 20% to 30% absorption, and the remainder is eliminated in the feces ([Fig. 1](#f0005){ref-type="fig"}; [@b0270], [@b0280]).Fig. 1Flow diagram of the pharmacokinetics of sulfasalazine on oral administration.

Distribution {#s0025}
------------

Absorbed sulfasalazine is distributed throughout the body but does not cross the blood--brain barrier. Both SSZ and sulfapyridine cross the placenta and are found in breast milk. Breast milk concentrations of sulfapyridine are approximately 40% of those seen in plasma, but SSZ concentrations are negligible. Plasma concentrations of mesalazine are very low, and it is therefore unlikely to be found in breast milk. Both sulfapyridine and SSZ distribute to synovial fluid, with concentrations generally lower than those found in plasma. The peak plasma level of sulfapyridine is attained later than SSZ. The plasma protein binding is up to 99% for SSZ and 50% for sulfapyridine ([@b0280]).

Metabolism and excretion {#s0030}
------------------------

Systemically absorbed sulfasalazine is metabolized to some extent in the liver to sulfapyridine and mesalazine ([@b0345]); a small proportion of an administered dose of SSZ is eliminated unchanged in the urine ([@b0280], [@b0330]). Sulfapyridine is primarily metabolized by acetylation in the liver to form N-acetyl-sulfapyridine (inactive), some of which is eliminated in the urine. Sulfapyridine and its N-acetyl metabolite also undergo hydroxylation and glucuronidation; the glucuronide conjugates and the hydroxylated metabolites (5-hydroxy-sulfapyridine and N-acetyl-5-hydroxy-sulfapyridine) are eliminated in the urine ([@b0280], [@b0330], [@b0345]).

Mesalazine is mainly (70%--80%) eliminated unchanged in the feces, but it also undergoes acetylation to form N-acetyl- mesalazine (inactive), which is eliminated in the urine ([Fig. 1](#f0005){ref-type="fig"}). The metabolism of sulfapyridine is affected by the acetylator phenotype. In the Caucasian population, there is an approximately equal distribution in fast and slow acetylators ([@b0270], [@b0330]). The elimination half-life of sulfapyridine ranges between 5 and 18 hours and is approximately 50% to 100% longer in slow acetylators than in fast acetylators. Slow acetylators have higher plasma concentrations of sulfapyridine, which is thought to be related to the higher prevalence of minor adverse effects ([@b0270], [@b0320], [@b0330]).

Mechanism of action {#s0035}
-------------------

The sulfa moiety is known to have antimicrobial properties, whereas the salicylate component acts as an anti-inflammatory agent. The mechanism of action of SSZ is summarized in [Table 1](#t0005){ref-type="table"} ([@b0010], [@b0055], [@b0070], [@b0075], [@b0125], [@b0130], [@b0140], [@b0150], [@b0165], [@b0170], [@b0175], [@b0205], [@b0270], [@b0275], [@b0285], [@b0305], [@b0365]).Table 1Mechanism of action of sulfasalazine.Action of sulfasalazineMechanismImmunomodulatory/anti-inflammatory actionInhibition of cytokine release•T-cell cytokine IL-2•Monocyte-macrophage cytokines IL-1, IL-6, IL-12, TNFInhibition of 5-lipoxygenase pathway•↓ leukotriene productionInhibition of nuclear factor-κβ transcription•↓ expression of adhesion molecules (VCAM, ICAM, ELAM)Inhibition of chemotaxis and random migration of inflammatory cells such as neutrophils↓ superoxide and proteolytic enzyme productionInhibition of 5-aminoimidazile-4-carboxamide ribonucleoside transformylase enzyme•↑adenosine at sites of inflammation↑free radical scavenging activityOther in vitro anti-inflammatory effects:•Inhibition of prostaglandin E2 synthetase•Apoptosis of neutrophils•Inhibition of the extracellular release of pro-inflammatory secretory phospholipase A2•B-cell suppression and immunoglobulin productionAntiproliferative actionCompetitive inhibitor of brush border folate conjugase enzyme•Inhibition of polyglutamyl folate hydrolysis•↓absorption of both polyglutamyl and monoglutamyl folateAntibacterial activityCompetitive inhibition of the bacterial enzyme dihydropteroate synthetase, necessary for the synthesis of folic acid[^1]

Dermatological uses {#s0040}
===================

The use of SSZ in rheumatoid arthritis and inflammatory bowel disease is supported by robust evidence ([@b0270], [@b0350]). The uses of SSZ in the field of dermatology are summarized in [Table 2](#t0010){ref-type="table"}.Table 2Review of literature on SSZ use in various dermatological diseases.S. No.Dermatological diseaseStudy (year)Sample sizeMaximum daily doseMaximum duration of treatmentOutcomeAdverse effects reported1.PsoriasisUncontrolled open-label study ([@b0155])323 g8 weeksTwenty-four patients completed the treatment, and 17 had modest to marked improvement or clearing.Nausea, indigestion, diarrhea, fatigue, cutaneous reactionDouble-blind placebo-controlled randomized study ([@b0160])504 g8 weeksIn the SSZ group, 7 of 17 patients had marked, 7 of 17 had moderate, and 3 of 17 had minimal improvement.\
In the placebo group, only 1 of 27 patients demonstrated moderate improvement.Cutaneous reactions, nauseaComparative randomized study ([@b0040])301.5 g12 weeksEfficacy was comparable for the 2 drugs: Decrease in mean EST in patients on methotrexate and SSZ therapy was 86.55% and 83.64% at 4 weeks and 92.86% and 92.13% at 12 weeks, respectively.Transient rise in transaminasesRandomized controlled trial ([@b0110])322 g8 weeksTwenty-one of 32 patients completed treatment. The percentage reduction in PASI score achieved with methotrexate was significantly higher than that with SSZ alone, PTX alone, or the combined use of SSZ and PTXNauseaCase report ([@b0215])11 g6 weeksSkin lesions disappeared after 6 weeks of treatmentNR2.Alopecia areataRetrospective record based ([@b0115])2494 gVariableOf the 19 patients who took SSZ for ≥ 3 months, 7 patients had excellent, 3 had slight, and 9 had no improvementGI distress, rash, laboratory abnormalities, headacheUncontrolled open-label study ([@b0005])263 g6 monthsTwenty-two patients completed treatment. Overall, 15 of 22 patients (68.2%) responded to therapy. Six of 22 (27.3%) achieved complete hair regrowth, and 40.9% had partial hair regrowth. Seven (31.8%) had no hair regrowth. Of the 22 patients with complete and partial remission, 10 (45.5%) had partial or complete relapseGI distress, rash, laboratory abnormalities, headache3.Lichen planusUncontrolled open-label study ([@b0035])203 g12 monthsComplete responses were observed in 13 patients and partial responses in 7 patients.\
All patients reported an early resolution of the pruritus. No changes were detected in mucosal lichen planusGI distress, cutaneous rash, leukopenia, poor glycemic controlDouble-blind, randomized, placebo-controlled study ([@b0250])522.5 g6 weeksTwenty-three patients in the SSZ group and 21 patients in the placebo group evaluated for efficacy.\
After 6 weeks of treatment, the rate of improvement was 9.6% (two patients) in the placebo group and 82.6% (19 patients) in the sulfasalazine group. The improvement rate of pruritus was 14.3% in the placebo group and 91.3% in the sulfasalazine groupSkin rash, headache, GI distress, mild leucopeniaUncontrolled open-label study ([@b0185])21Topical SSZ 3 times/day4 weeksSeventeen patients (81%) reported improvement of discomfort and 12 patients (57%) had lesions decrease in size \> 50%NR4.Pemphigus vulgarisComparative, double-blind study ([@b0105])64SSZ 1.5 g (+PTX 1.2 g)[\*](#tblfn1){ref-type="table-fn"}VariableForty-two patients received SSZ+PTX and 22 patients received placebo. A statistically significant decrease in serum levels of TNF-alpha in the SSZ group compared with those in placebo group at 6 and 8 weeks. Significant clinical improvement was observed in patients in the SSZ group compared with those in the placebo group.Gastric pain, nausea, and headacheUncontrolled, open-label study ([@b0095])15SSZ 1.5 g (+PTX 1.2 g)[\*](#tblfn1){ref-type="table-fn"}VariablePatients achieved remission period ranging from 6 months to 3 yearsNausea, vomiting, headache, and fatigue5.Dermatitis herpetiformisCase report ([@b0355])24 gVariable--NR6.Mucus membrane pemphigoidRetrospective study ([@b0090])94 gNRDisease remained controlled with SSZ alone in four patients (45%). Two patients (22%) required adjunctive oral cyclophosphamideGI discomfort, hemolysis7.UrticariaRetrospective study ([@b0235])194 g24 monthsFourteen patients (74%) reported significant improvement, four patients (21%) reported minimal improvement but were not satisfied with their symptom relief, and one patient (5%) reported worsening of symptomsHeadache, GI discomfort, leukopenia, elevated liver enzymesRetrospective study ([@b0255])393 g74 weeks (mean)Eight patients were excluded from the final analysis. Twenty-six patients (83.9%) showed an improvement in symptoms within the first 3 months, with 51.6% of patients becoming asymptomatic within the first 6 months of starting SSZ. Eleven patients (35.4%) achieved complete relief of symptoms after tapering off SSZ therapy. Five of the 31 patients (16.1%) failed treatmentLeucopenia, anemia, raised transaminases, rhabdomyolysisCase report ([@b0120])24 gNR-NR8.DLEPilot study ([@b0030])134.5 g3 months-Headache, nausea, epigastric painCase series ([@b0085])112 gNRSeven patients had complete response, one had partial response, and 3 were nonresponders. Six of eight responders were given SSZ exclusivelyLight sensitization, neutropenia, transient rise in liver enzymes9.Atrophie blancheCase report ([@b0160])23 gVariable-NRCase series ([@b0050])83 g2 months-Facial edema, lip paresthesia10.Generalized morpheaCase report ([@b0325])12 g7 monthsMarked decrease in the infiltration of the plaques and restoration of the mobility of the affected areas after 1 month of treatment with SSZNRCase report ([@b0240])12 g8 months--NR11.PD-PSVCase report ([@b0220])10.5 gNR--NR12.EEDCase report ([@b0080])1NRNRPatient reported full remission of EED symptoms soon after initiation of SSZNR[^2][^3]

Psoriasis and psoriatic arthritis {#s0045}
---------------------------------

SSZ has been tried successfully alone and in combination with pentoxifylline in patients with psoriasis ([@b0040], [@b0110], [@b0150], [@b0155]) and psoriatic arthritis ([@b0190], [@b0230]) owing to its anti-inflammatory and antiproliferative action. The prescribed dose ranges from 1500 mg/day to 3 g/day.

Reductions have been observed in ICAM-1 expression, leukotriene synthesis, and in the number of intraepidermal and dermal T lymphocytes, as well as T-helper CD4 cells in the skin biopsy specimens of patients affected by psoriasis and treated with SSZ ([@b0150]). SSZ was also found to be effective in a case of acrodermatitis continua of Hallopeau ([@b0215]).

Alopecia areata {#s0050}
---------------

SSZ in a dose of 500 mg twice daily for 1 month, 1 g twice daily for 1 month, and then 1.5 g twice daily for a maximum of 3 months was used in recalcitrant cases of alopecia areata with good response in 27% of cases ([@b0005]). [@b0115] reported a 23% response in severe cases of alopecia areata ([@b0115]).

Lichen planus {#s0055}
-------------

In a prospective uncontrolled study of 20 patients with lichen planus (LP), SSZ at initial doses of 1.5 g/day and increased by 0.5 g/week to 3 g/day for 4 to 16 weeks yielded a complete response in 13 patients and a partial response in 7 patients. Patients with mucosal LP showed a poor response ([@b0035]).

A randomized, double-blind, placebo-controlled, prospective study of 52 patients with LP concluded that SSZ is a relatively safe and effective alternative treatment option for generalized LP ([@b0250]). SSZ has also been tried in a topical formulation as a mouthwash in oral LP with good results ([@b0185]).

Immunobullous disorders {#s0060}
-----------------------

In a comparative double-blind study, a combination of SSZ and pentoxifylline used as adjuvant therapy in the treatment of PV induced a faster and more significant decrease in the serum level of tumor necrosis factor alpha (TNF-α), and this decrease was associated with rapid clinical improvement. These adjuvant therapies can replace cyclophosphamide, especially in younger patients, owing to their relatively fewer side effects ([@b0095], [@b0105]).

SSZ is one of the first-line drugs for the management of ocular mucus membrane pemphigoid, alongside dapsone. Incidence of complications is also less frequently reported with SSZ than with dapsone ([@b0090], [@b0310]). However, limited data exist on the use of SSZ in other bullous disorders, such as dermatitis herpetiformis ([@b0355]).

Urticaria and angioedema {#s0065}
------------------------

Sulfasalzine has been effectively tried in antihistamine-resistant cases of chronic idiopathic urticaria and angioedema ([@b0235], [@b0255]). An isolated case has been reported of the usefulness of sulfasalzine in delayed pressure urticaria ([@b0120]).

Pyoderma gangrenosum, erythema elevatum diutinum, and Behcet's disease {#s0070}
----------------------------------------------------------------------

Anecdotal cases have been reported on the successful use of SSZ in pyoderma gangrenosum and erythema elevatum diutinum ([@b0045], [@b0080], [@b0245]). Low-dose SSZ has also been successfully used in a case of pyodermatitis-pyostomatitis vegetans ([@b0220]). SSZ along with steroids is the first-line treatment for gastrointestinal Behcet's disease ([@b0020]).

Atrophie blanche {#s0075}
----------------

Anecdotal reports exist on the use of SSZ in atrophie blanche ([@b0050], [@b0160]).

Discoid lupus erythematosus {#s0080}
---------------------------

SSZ has been tried in the treatment of discoid lupus erythematosus. In one study comprising 11 cases, SSZ was found to be more effective in rapid acetylators ([@b0030], [@b0085]).

Morphea and lichen sclerosus et atrophicus {#s0085}
------------------------------------------

Generalized bullous morphea and generalized morphea with Lichen sclerosus et atrophicus was successfully treated with SSZ in occasional case reports ([@b0240], [@b0325]).

Miscellaneous {#s0090}
-------------

Anecdotal reports exist on the use of SSZ in combination and sequential therapy with other DMARDs in the management of SAPHO syndrome with good response ([@b0180], [@b0260]). The use of SSZ has also been reported in adult-onset still disease, but it should be used with caution owing to the high incidence of adverse effects ([@b0200]).

Dosage and administration {#s0095}
=========================

SSZ is available in regular and enteric coated tablets of 500 mg and a suspension of 500 mg/ml. The dose is gradually titrated to minimize gastrointestinal adverse effects. The initial recommended dosage is 500 mg daily, escalated by 500 mg/day every week to the standard dose of 1500 to 3000 mg daily in divided doses. If a patient is intolerant of a new dose level, the dose should be reduced to a previously tolerated level for a further week and then increased again as appropriate. In pediatric patients, the initial dose is 10 to 12.5 mg/kg/day, which is increased weekly at 50 mg/kg/day in two divided doses until a maintenance of 2 g/day is achieved ([@b0015], [@b0075]).

Concomitant folic acid supplementation is advised because SSZ reduces folate absorption and is an inhibitor of the folate-dependent pathway. The dose should be reduced for patients with renal insufficiency ([@b0075]).

Adverse effects {#s0100}
===============

Most adverse events due to SSZ occur during the first few months of treatment, and occurrences decrease with time. The most common adverse effects are gastrointestinal effects, headache, dizziness, and rash ([@b0280]).

Gastrointestinal and hepatic {#s0105}
----------------------------

The most frequently reported adverse effects with SSZ therapy are gastrointestinal effects (nausea, vomiting, dyspepsia, anorexia, abdominal pain, and diarrhea). SSZ is therefore prescribed as enteric coated tablets for most patients to minimize gastrointestinal effects. Elevated levels of liver enzymes and hepatic dysfunction are reported less frequently and are mostly transient ([@b0075]).

Hematologic {#s0110}
-----------

Hematologic disturbances are reported in ≤3% of SSZ recipients and usually occur within the first 3 months. Leukopenia is the most common abnormality and usually reverses after discontinuing SSZ. The incidence of hematologic disturbances is higher in patients with rheumatoid arthritis than in patients receiving the drug for other diagnoses.

Macrocytosis due to folate deficiency and hemolysis have been reported with SSZ; its use should be avoided in patients with G6PD deficiency. Thrombocytopenia is rare ([@b0075], [@b0210]).

Dermatologic {#s0115}
------------

The sulfapyridine moiety in SSZ is believed to be responsible for most of the hypersensitivity reactions that occur. Cutaneous rashes are reported in \<5% of patients and are usually maculopapular, pruritic, and generalized ([@b0075]). Anecdotal reports exist of occurrences of erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, lichenoid eruption, lupus-like syndrome, and phototoxicity ([@b0145], [@b0195], [@b0300], [@b0335], [@b0340]).

Raynaud phenomenon, thinning of the hair, and cutaneous pigmentation have also been reported with SSZ use ([@b0295], [@b0065], [@b0135]).

Central nervous system {#s0120}
----------------------

Headache and dizziness are the most common neurologic side effects ([@b0270], [@b0280]). Axonal neuropathy may occur after prolonged SSZ use but is very rare ([@b0225]).

Fertility {#s0125}
---------

Prolonged treatment with SSZ may universally depress semen quality (i.e., increase the number of abnormal forms and impaired sperm motility) and cause oligospermia, leading to infertility. However, the condition appears to be reversible upon discontinuation of the drug, returning to normal 2 to 3 months after cessation. SSZ has no effect on fertility in women ([@b0075], [@b0270]).

Pregnancy and lactation {#s0130}
-----------------------

SSZ and sulfapyridine cross the placenta, but they do not seem to cause or increase fetal anomalies, spontaneous abortions and therefore can be safely used in women of childbearing age and pregnant women. However, it should be used with caution owing to reports of neural tube defects and hematological complications, such as hemolytic anemia in the fetus. Administration of folic acid (5 mg/day) with SSZ is recommended during pregnancy to decrease the risk of neural tube defects.

Sulfapyridine is secreted in breast milk. The American Academy of Pediatrics has classified SSZ as a drug that must be given with caution to nursing women, especially in cases of premature infants and those with G6PD deficiency due to an increased risk of hemolytic anemia and jaundice ([@b0060], [@b0360]).

Pulmonary {#s0135}
---------

Pulmonary toxicity due to SSZ is rare. Typical presentation of SSZ-induced lung disease is new-onset dyspnea and infiltrates on chest radiography. Pulmonary pathology is variable, the commonest being eosinophilic pneumonia with peripheral eosinophilia and interstitial inflammation with or without fibrosis ([@b0265]).

Monitoring {#s0140}
==========

Complete blood counts and liver and renal function tests should be performed prior to commencing therapy. These tests should be repeated every 2 to 4 weeks for the first 3 months and then every 8 to 12 weeks for the next 3 months of treatment. Beyond 6 months of therapy, longer intervals (12 weeks) of monitoring are suggested. Patients should be advised to report immediately in case of fever, sore throat, malaise, or nonspecific illness ([@b0290]).

Drug interactions {#s0145}
=================

SSZ inhibits thio-purine methyl transferase enzyme activity and thus may potentiate azathioprine toxicity ([@b0025]). SSZ reduces the absorption of folic acid and digoxin ([@b0345]). Rarely, SSZ can increase the effects of oral hypoglycemic drugs and the anticoagulant effect of warfarin ([@b0075]).

Contraindications {#s0150}
=================

Contraindications to SSZ include Hypersensitivity to any component of SSZ, or with a sulfonamide or salicylate allergy ([@b0290]); thrombocytopenia (platelet count \<50,000/mm^3^; [@b0290]); hepatic disease (e.g., liver transaminases \>2-fold the upper limit of normal, acute hepatitis B or C, untreated chronic hepatitis B; [@b0290]); significant renal impairment ([@b0290]); porphyria ([@b0075]); and G6PD deficiency ([@b0075]).

Discussion {#s0155}
==========

SSZ is approved by the U.S. Food and Drug administration for the management of ulcerative colitis and rheumatoid arthritis. It has been used for a variety of dermatological diseases, such as psoriasis, alopecia areata, pemphigus vulgaris, urticaria, and mucus membrane pemphigoid. However, its use in dermatology is limited by the lack of randomized trials.

We could find only a few randomized controlled trials supporting its use in psoriasis ([@b0040], [@b0160]), lichen planus ([@b0250]), and pemphigus vulgaris ([@b0105]). The use of SSZ in other dermatological diseases is largely supported by uncontrolled trials, case series, and case reports.

Conclusions {#s0160}
===========

SSZ is an inexpensive drug that has immunomodulatory, anti-inflammatory, and antiproliferative properties with relatively few side effects. The wide range of applications of SSZ in varied dermatological diseases makes it an important drug in the therapeutic arsenal of a dermatologist. SSZ can be especially useful in patients who fail to respond to standard therapy or in those for whom standard therapy is contraindicated. However, the therapeutic potential of the drug in the field of dermatology needs to be further established by multicenter, large-scale randomized controlled trials.
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[^1]: ELAM, endothelial cell adhesion molecule; ICAM, intercellular adhesion molecule; IL, interleukin; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule.

[^2]: DLE, discoid lupus erythematosus; EED; erythema elevatum diutinum; EST, erythema, scaling, and thickness; GI, gastrointestinal; NR, not reported; PASI, Psoriasis Area and Severity Index; PD-PSV, pyodermatitis-pyostomatitis vegetans; PTX, pentoxifylline; SSZ, sulfasalazine; TNF, tumor necrosis factor.

[^3]: Combined therapy with IV pulsed steroid.
